Last reviewed · How we verify
Bortezomib,Pirarubicin,Dexamethasone
Bortezomib,Pirarubicin,Dexamethasone is a Small molecule drug developed by Second Military Medical University. It is currently FDA-approved.
At a glance
| Generic name | Bortezomib,Pirarubicin,Dexamethasone |
|---|---|
| Sponsor | Second Military Medical University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bortezomib,Pirarubicin,Dexamethasone CI brief — competitive landscape report
- Bortezomib,Pirarubicin,Dexamethasone updates RSS · CI watch RSS
- Second Military Medical University portfolio CI
Frequently asked questions about Bortezomib,Pirarubicin,Dexamethasone
What is Bortezomib,Pirarubicin,Dexamethasone?
Bortezomib,Pirarubicin,Dexamethasone is a Small molecule drug developed by Second Military Medical University.
Who makes Bortezomib,Pirarubicin,Dexamethasone?
Bortezomib,Pirarubicin,Dexamethasone is developed and marketed by Second Military Medical University (see full Second Military Medical University pipeline at /company/second-military-medical-university).
What development phase is Bortezomib,Pirarubicin,Dexamethasone in?
Bortezomib,Pirarubicin,Dexamethasone is FDA-approved (marketed).